By Fineline Cube 
China-Based Livzon Pharmaceutical Group, a holding subsidiary of Joincare Pharmaceutical (SHA: 600380) announced that the Phase III trial of LZM012, an IL-17A/F dual-targeted humanized monoclonal antibody developed in collaboration with Beijing Kanova Biopharmaceutical, has achieved its primary endpoint in patients with moderate-to-severe plaque psoriasis.
Clinical Trial Results
The multicenter, randomized, double-blind, secukinumab-controlled study demonstrated a 49.5% PASI 100 response rate at Week 12 for LZM012, compared to 40.2% for the comparator, establishing non-inferiority and statistical superiority. Additionally, PASI 75 responses at Week 4 reached 65.7% for LZM012 versus 50.3% for the comparator, indicating a faster onset of action. Sustained efficacy was observed at Week 52, with PASI 100 rates of 75.9% and 62.6% under two maintenance-dose regimens. The safety profile of LZM012 was consistent with previous clinical data.
Regulatory Progress
Livzon Pharmaceutical Group, a controlling subsidiary of Joincare, has filed a pre-NDA meeting request with China’s Center for Drug Evaluation to advance LZM012 toward market approval.-Fineline Info & Tech